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mammography at age 40. OBJECTIVE: To develop a prelimi-
nary model to evaluate the cost-effectiveness of these guidelines,
using similar assumptions and clinical trial evidence sources for
the breast cancer mortality beneﬁt as the ACS. METHODS:
Interventions: Annual mammography until age 70 vs. no annual
mammography. Design: Age-speciﬁc discounted lifetime costs
and discounted quality-adjusted life expectancy were estimated
for each intervention, and the incremental cost-effectiveness ratio
(ICER) calculated. Life-expectancy estimates were generated by
Markov model simulation starting from age 40. Direct costs
included the management of early-stage and invasive breast
cancer, and the costs of mammography and the workup of a pos-
itive result. Indirect costs accounted for the time spent getting
mammograms. BC management costs with and without mam-
mography were assumed to be the same. Time Horizon: Life-
time. Perspective: Societal. Target Population: The model was
estimated in white females aged 40 and over. Data Sources: RCT
Meta-analysis evidence sources used by the ACS, SEER data for
BC mortality and life expectancy, NCHS life-tables data, studies
of mammography performance, and quality of life/health utility
studies. Sensitivity analysis was done to the discount rate, costs,
sensitivity of mammography and costs of mammography.
RESULTS: Base-Case Analysis: The ICER for annual mammog-
raphy until age 70 was extremely high with a minimum value of
$347,442/QALY at age 60. Annual mammography until age 80
was slightly more cost-effective, ranging from $424,058/QALY,
$323,893/QALY and $271,773/QALY at ages 40, 55, and 70
respectively. CONCLUSIONS: Annual mammography starting
from age 40 may turn out to be a very expensive policy. However,
the economic model has some limitations: the mammography
intervention may be associated with different BC management
costs; and the data sources for BC mortality reduction with
mammography have been widely disputed.
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OBJECTIVE: Prostate cancer can have signiﬁcant physical, psy-
chological, and social impact on patients, particularly early in
the treatment course. While psychological intervention during
oncologic care has been shown to improve all aspects of well-
being, few studies have focused on men diagnosed with prostate
cancer or have targeted the period between diagnosis and treat-
ment. We evaluated the efﬁcacy of an innovative, brief psy-
chosocial counseling program delivered to men before and after
prostate cancer treatment. METHODS: One hundred thirty-two
men diagnosed with prostate cancer were randomly assigned to
either intervention (n = 69) or control (n = 63) groups. Partici-
pants completed the Proﬁle of Mood States (POMS), Index of
Coping Responses (ICR), and scales measuring general and
disease-speciﬁc HRQOL, at baseline (before treatment com-
menced) and at months 3 and 12. Both groups received standard
medical care; and intervention participants received 2 sessions of
counseling before treatment and one session 4 to 6 weeks after
treatment completion. RESULTS: Intervention effects were eval-
uated using a mixed model analysis, adjusting for cancer treat-
ment (radiation or surgery) and time. There were no signiﬁcant
differences between groups at baseline on the demographic or
psychosocial measures. In the mixed model, intervention partic-
ipants reported signiﬁcant improvements over time on three out-
comes: Vigor (POMS; p < 0.05) and Information Seeking and
Affective Regulation (ICR; p < 0.01 and p < 0.05, respectively).
CONCLUSIONS: While the brief intervention did not appear to
inﬂuence HRQOL, or prostate-speciﬁc symptoms, it improved
energy level and coping responses, particularly those relevant to
managing information and emotions. These coping strategies
may be especially important given the decision-making and treat-
ment initiation tasks of early prostate cancer care. Source of
ﬁnancial support: California Cancer Research Program Grant
#97–12013.
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THE EUROPEAN ORGANIZATION FOR RESEARCH AND
TREATMENT OF CANCER QUALITY OF LIFE CORE
QUESTIONNAIRE (EORTC QLQ-C30): VALIDATION OF
ENGLISH VERSION IN SINGAPORE
Xie F, Luo N, Li SC
National University of Singapore, Singapore, Singapore
OBJECTIVE: To assess the validity and reliability of EORTC
QLQ-C30 in patients with cancer in Singapore. METHODS: A
total of 62 patients at Cancer Center of National University
Hospital were asked to complete independently QLQ-C30 and
a generic questionnaire (SF-36). The sociodemographic data
were obtained simultaneously. RESULTS: The QLQ-C30
demonstrated good internal reliability for most scales with 
Cronbach’s alpha more than 0.7 except cognitive functioning,
physical functioning, and nausea and vomiting scale. The major-
ity of item-scale Pearson’s coefﬁcients (corrected for overlap)
were more than 0.4 and higher as opposed to that between the
item and competing scales in the same instrument. All function-
ing scales in QLQ-C30 had strong correlations with the scales
measuring the similar aspect of QoL in SF-36. The correlation
coefﬁcients among all scales were signiﬁcant but modest (ranging
from an absolute value of 0.23 to 0.65). CONCLUSION: In our
study, QLQ-C30 could be considered reliable and valid using to
evaluate health related quality of life (HRQoL) in cancer patients
in Singapore.
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OBJECTIVE: The majority of head and neck cancer (HNC)
patients undergoing radiation experience xerostomia (dry
mouth) which can range from mild to severe, even after com-
pletion of treatment. Its impact on quality of life (QoL) can be
signiﬁcant. The objective of this study was to evaluate the psy-
chometric properties of a new questionnaire developed to assess
the impact of xerostomia on QoL. METHODS: Data were
obtained from radiation patients (RP) participating in the Eval-
uating Cytoprotection Health Outcomes (ECHO) Registry.
ECHO, a prospective, longitudinal study of patients receiving
amifostine prior to radiation and/or chemotherapy, collects clin-
ical and outcomes information. All RP complete a questionnaire,
including the Functional Assessment of Cancer Therapy-General
(FACT-G) and a new questionnaire assessing xerostomia symp-
toms (XSQ) at baseline, 6-weeks (completion of radiation), and
at 6 weeks, 3 months, and 6 months post treatment. RESULTS:
A total of 104 with HNC, 43 with non-small cell lung cancer
(NSCLC), and 38 with other cancer completed the questionnaire.
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The majority were male, Caucasian, and insured. Average age
was 59 years old. Based on variable clustering, the XSQ pro-
duced three scales—Xerostomia Interference (9-items), Pain (5-
items), and Nausea and Vomiting Symptoms (3-items). Overall,
internal consistency was acceptable (Cronbach’s alpha coefﬁ-
cients ranged from 0.81–0.96). Construct validity was demon-
strated based on correlations between related items/scales.
Known groups validity was upheld, as HNC patients reported
statistically signiﬁcantly lower scale scores (worse functioning)
than NSCLC patients on all three domains (p < 0.05). As
expected, no statistically signiﬁcant differences were reported
between the groups on the FACT-G scales. CONCLUSIONS:
The XSQ was found to be reliable and valid in this population
and should be a useful tool for clinicians to monitor their
patients. Responsiveness will be evaluated in the future. The
ECHO Registry is currently ongoing.
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OBJECTIVE: Demographic, clinical, social and economic
factors inﬂuence the Health Related Quality of Life (HRQOL)
and must be assessed in the management and treatment of
diverse prostate cancer (PC) patients. The study objective is to
analyze the variations in QoL of newly diagnosed PC patients
over the course of three months between public and private facil-
ities. METHODS: A total of 316 newly diagnosed PC patients
recruited from the urology clinics of a private urban academic
hospital and a veterans hospital completed SF-36 and UCLA-PCI
prior to treatment, and at 3-month follow-up. RESULTS:
General and Prostate-Speciﬁc QoL and demographics were com-
pared across public and private facilities using t-test and chi-sq.
Demographic characteristics varied signiﬁcantly between the two
groups. Privately-treated patients were predominantly Caucasian
(83.68%), whereas publicly-treated patients were predominantly
African American (66.23%, p < 0.0001). Privately-treated
patients had signiﬁcantly higher income and education levels,
and were signiﬁcantly more likely employed and married
(61.35% vs. 20.00%; 54.59% vs. 14.29%). Baseline mean
scores of general QoL demonstrated that publicly-treated
patients were substantially less healthy by physical, psychologi-
cal and social measures (mean physical function score of 47.53
compared to 70.46 for privately-treated patients (p < 0.0001)).
This was true for the PC-speciﬁc HRQoL also, though the dif-
ferences were smaller. After three months, the mean scores for
both groups declined from baseline levels though the groups’ rel-
ative divergence narrowed. Publicly-treated patients remained
substantially less healthy as indicated by general HRQoL scores.
However, for PC-speciﬁc QoL, their means scores on sexual and
urinary function, and sexual and urinary bother were signiﬁ-
cantly higher than privately-treated patients. CONCLUSIONS:
Baseline and 3-month HRQoL of newly diagnosed PC-patients
vary across different treatment settings. Further analysis into the
baseline determinants of QoL and their effect on subsequent
changes in QoL are crucial for effective management of prostate-
cancer. Acknowledgement: Supported by the DOD Prostate
Cancer Research Program DAMD17-02-1-0126.
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OBJECTIVES: Although there is no documented survival differ-
ence between 3-dimensional conformal radiation therapy
(3DCRT) and prostate-brachytherapy (PB), some studies suggest
a quality of life (QOL) advantage with PB. This study assessed
patient preferences for risk of impotence and incontinence after
PB and 3DCRT. METHODS: Preferences for PB were compared
to age, Gleason-grade and pretreatment-PSA matched controls
treated with 3DCRT, using a modiﬁed Time Trade-Off interview.
Men with PB (permanent I-125 implants) were 0.78 to 4.22
(median 2.24) years post treatment (PT) with 145Gy and men
with 3DCRT were 0.75 to 6.07 (median 2.33) years PT with 74
Gy (37 fractions) to the prostate. RESULTS: Preferences were
elicited from 51 men, (17 PB cases vs. 34 3DCRT matched con-
trols). Mean age for the cases and controls were 62.2 years and
63.6 years, respectively. Mean pretreatment-PSA and Gleason
scores were 7.1ng/ml and 5.9 for cases and 6.6ng/ml and 6.0 for
controls, respectively. There were no signiﬁcant differences
among cases and controls regarding race, education or income.
Differences in utilities were assessed using the Wilcoxon Test
(one-sided). Utilities for a 40% risk of impotence were 0.96
(SD.08) for cases and 0.91 (SD.16) for controls, which were not
signiﬁcant (p = 0.09). However, utilities for an 80% risk of impo-
tence were 0.93 (SD.12) for cases and 0.85 (SD.18) for controls
(p = 0.03). Utilities for a 30% risk of incontinence were 0.96
(SD.12) for cases and 0.85 (SD.22) for controls (p = 0.008). Util-
ities for a 10% risk of incontinence were 0.98 (SD.06) for cases
and 0.91 (SD.21) for controls (p = 0.05). CONCLUSIONS:
Patients treated with PB have signiﬁcantly higher utilities for
most levels of risk associated with impotence and incontinence
as compared to those treated with 3DCRT. This is possibly
related to either actual or perceived better sexual and urinary
QOL for PB as compared to 3DCRT.
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OBJECTIVES: To test whether individuals’ responses to stan-
dard gamble (SG) and visual analogue scale (VAS) questions do
not depend on the time horizon of the health scenario presented.
METHODS: Face-to-face interviews were conducted in a con-
venience sample aged 24 to 59 years at a Southern University in
the US (n = 14). Preferences were estimated using SG and VAS.
Individuals rated their preferences for three health states of
varying severity of post chemotherapy nausea and vomiting
(PCNV) assuming different time horizons. Repeated measures
analysis of variance (ANOVA) were conducted (SX6X2) for each
health state to determine the affect of TIME (levels: 3 days, 3
months, 1 year, 5 years, 20 years and rest of life) and METHOD
(levels: SG and VAS) on preference. RESULTS: Analysis showed
that the time horizon used did affect an individual’s preference
rating for SG and VAS. For all three models tested (OP, ST, NV),
main effects TIME (F(5,65) = 10.71, F(5,65) = 13.85, F(5,65) =
17.40) and METHOD (F(1,13) = 34.56, F(1,13) = 58.01, F(1,13)
